Corporate Member Council Representative:
Stephanie Otis and Olga Milobedski
Ferring is a privately owned, international pharmaceutical company that specializes in the research, development and commercialization of compounds in infertility, general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and orthopedics. In the U.S. Ferring’s infertility portfolio includes BRAVELLE® (urofollitropin for injection, purified), MENOPUR®, (menotropins for injection, USP), REPRONEX® (menotropins for injection, USP) and NOVAREL™ (chorionic gonadotropin for injection, USP). Ferring also offers the exclusive Q∙CAP™vial adapter, for needle-free reconstitution of its infertility treatments.